FAKTOR-OPTIONSSCHEIN - GILEAD SCIENCES | Market Closed - Deutsche Boerse AG 20:41:32 21/06/2024 BST | ||
| 0.09 EUR | -25.00% |
|
| Current month | -70.97% | ||
| 1 month | -59.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
| Date | Price | Change |
|---|---|---|
| 21/06/24 | 0.09 | -25.00% |
| 20/06/24 | 0.12 | -61.29% |
| 19/06/24 | 0.31 | +3.33% |
| 18/06/24 | 0.3 | +20.00% |
| 17/06/24 | 0.25 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 21, 2024 at 08:41 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SN79SV |
| ISIN | DE000SN79SV2 |
| Date issued | 18/08/2022 |
| Strike | 66.29 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 16.06 € |
|---|---|
| Lowest since issue | 0.054 € |
| Spread | 0.01 € |
| Spread % | 10.00% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
70.67
USD
Average target price
82.7
USD
Spread / Average Target
+17.02%
- Stock Market
- Certificates
- Certificat
